1.Ji Youl Lee,et al.BJU Int. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.2004 Oct;94(6):817-20. 2.2019版中国泌尿外科和男科疾病诊断治...
May 13, 2004 (San Francisco) — Several symptoms of benign prostatic hyperplasia (BPH) respond to injections of botulinum toxin A (Botox), according to findings presented here at the 99th annual meeting of the American Urological Association. "We hope that botulinum toxin A injections could be ...
之后,美国泌尿外科学会与欧洲泌尿外科学会分别在2003年和2004年对各自的BPH诊疗指南进行了更新。由于社会文化发展的不同,各国泌尿外科学会制定BPH诊疗指南的侧重点也有所不同。美国以及欧洲泌尿外科学会制定的BPH诊疗指南重视主观因素的结果,如采用国际前列腺症状评分(international prostate symptom score,I-PSS)与生活质量...
Curr Opin Urol,2004,14: 1-6 五、BPH的治疗 下尿路症状是BPH患者的切身感受,最为患者本人所重视。由于患者的耐受程度不同,下尿路症状及其所致生活质量的下降是患者寻求治疗的主要原因。因此,下尿路症状以及生活质量的下降程度是治疗措施选择的重要依据。应充分了解患者的意愿,向患者交代包括观察等待、药物治疗、...
Lukacs等人分析了2004-2008年法国的处方情况发现,BPH术后药物治疗的比例很高[3,4]。(如下图) 随着BPH认知的深入、治疗药物及方式多样化,综合严格的评估诊断、更好的风险分层与识别以及对患者意愿的充分了解将成为治疗成功能的关键。同时这也使得BPH个体化治疗成为现实的需求。
BPH -0.001 -10.53% Apr 4, 2025 3:59 p.m. AEDT Delayed quote About BPH Energy Ltd. BPH Energy Ltd. engages in the provision of investments in biotechnology and oil and gas exploration entities. The company was founded in 2004 and is headquartered in Stirling, Australia. ...
1次拔管后1个月TRUS:前列腺体积52ml血清tPSA3.1ng/ml,fPSA0.9ng/ml马沙尼(经济原因):IPSS16分QOL3分2004年4,5月,再发AUR2次上海XX医院建议:TURP性功能要求较高马沙尼+非那雄胺IPSS12分QOL1-2分,未再发AUR2006年5月TRUS:前列腺体积35ml血清tPSA1.65ng/ml,Qmax14.2ml/s2006年11月要求停药建议停用马...
Chapple 2004 CHAPPLE, C. R.: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. In: BJU Int 94 (2004), Nr. 5, S. 738–44DGU Guideline, “S2e Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS...
[1]吴阶平.吴阶平泌尿外科学[M].山东:山东科学技术出版社, 2004:1127~1140. [2]SCHRODER A, UVELIUS B, CAPELLO SA, et al. Regional differences in bladder enlargementand in vitro contractility after outlet obstruction in ...
May 12, 2004 (San Francisco) -- The extended-release formulation of tolterodine (Detrol LA), often used to treat overactive bladder in women, is also effective in men with urinary frequency due to benign prostatic hyperplasia (BPH), according to findings presented here at the 99th annual mee...